ECOR1 CAPITAL LLC
Q3 2026 Form 13-F

SAN FRANCISCO, CALIFORNIA
CIK 0001587114 · CRD 167121 · SEC-registered investment adviser
$2.3B Reported Value Total

ECOR1 CAPITAL, LLC reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $3,424,668,843, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
5 funds · $3.4B gross asset value
Hedge Fund: $3.4B · Venture Capital Fund: $65.4M
Source: Form ADV filed 2026-03-30
Reported value
$2.3B
Quarter over quarter
-6.1%
Holdings
34
Top-10 concentration
83.1%

Filing Structure

Reports holdings for

  • NODELMAN OLEG (not a 13F filer in our records) · File #028-16767 · Q4 2014 – Q4 2014

Key People

Form ADV owners & control persons
Sarah Christine Marriott
MEMBER, CCO, COO
Oleg Nmn Nodelman
MANAGER
Scott Eric Perlen
CFO

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $2.3B
Positions 34
Change in reported value +9.5%
New positions 9
Exited positions 6
Position turnover 37.5%
Top-10 concentration 83.1%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
34 $2.3B
Q2 2026 13F
Filed Aug 14, 2026
31 $2.1B
Q1 2026 13F
Filed May 15, 2026
29 $2.4B
Q4 2025 13F
Filed Feb 17, 2026
28 $2.2B
Q3 2025 13F
Filed Nov 14, 2025
30 $2.1B
Q2 2025 13F
Filed Aug 14, 2025
36 $1.7B
Q1 2025 13F
Filed May 15, 2025
44 $1.7B
Q4 2024 13F
Filed Feb 14, 2025
55 $2.6B
Q3 2024 13F
Filed Nov 14, 2024
63 $2.9B
Q2 2024 13F
Filed Aug 14, 2024
55 $3.3B
Q1 2024 13F
Filed May 15, 2024
57 $4.0B
Q4 2023 13F
Filed Feb 14, 2024
51 $3.9B
Q3 2023 13F
Filed Nov 14, 2023
49 $3.0B
Q2 2023 13F
Filed Aug 14, 2023
51 $4.1B
Q1 2023 13F
Filed May 15, 2023
58 $3.1B
Q4 2022 13F
Filed Feb 14, 2023
66 $3.3B
Q3 2022 13F
Filed Nov 14, 2022
75 $3.4B
Q2 2022 13F
Filed Aug 15, 2022
78 $2.9B
Q1 2022 13F
Filed May 16, 2022
86 $3.2B
Q4 2021 13F
Filed Feb 14, 2022
75 $3.1B

28 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 ZYME ZYMEWORKS INC $608.5M 27.01%
2 ANAB ANAPTYSBIO INC $396.1M 17.58%
3 BMY C BRISTOL-MYERS SQUIBB CO $218.4M 9.7%
4 CGON CG ONCOLOGY INC $132.7M 5.89%
5 ETON ETON PHARMACEUTICALS INC $127.2M 5.65%
6 TRAX FIRST TRACKS BIOTHERAPEUTICS $112.5M 4.99%
7 AKTS AKTIS ONCOLOGY INC $93.9M 4.17%
8 CRSP CRISPR THERAPEUTICS AG $76.9M 3.41%
9 ANRO ALTO NEUROSCIENCE INC $57.0M 2.53%
10 LKFT LAKEFRONT BIOTHERAPEUTICS NV $49.4M 2.19%
11 ERAS ERASCA INC $43.2M 1.92%
12 ORIC ORIC PHARMACEUTICALS INC $40.8M 1.81%
13 NGNE NEUROGENE INC $35.4M 1.57%
14 ATTO ATTOVIA THERAPEUTICS INC $34.7M 1.54%
15 FULC FULCRUM THERAPEUTICS INC $25.2M 1.12%
16 ADRX ADARX PHARMACEUTICALS INC $22.9M 1.02%
17 STOK STOKE THERAPEUTICS INC $21.7M 0.96%
18 ZBIO ZENAS BIOPHARMA INC $21.3M 0.95%
19 ETRA ELECTRA THERAPEUTICS INC $19.1M 0.85%
20 ATRA ATARA BIOTHERAPEUTICS INC $13.2M 0.59%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings